Television Show Longevity by Network

Previously, I explored how to find the Golden Age of television by analyzing IMDb data. After I wrote this, Gabriel Rossman, an assistant of sociology at UCLA, noted that it would be interesting to see what this chart would look like if broken down by broadcast network. With Rossmans help (he also had been playing with the IMDb data), I was able to examine the average television show length over time, in number of episodes, for the different networks. A chart with the results is below:

Clearly, in the past decade or so, the number of episodes per show has calmed down quite a bit. My hunch is that this is due to the larger number of shows that are currently being aired, of which many get canceled, lowering the mean number of episodes. But if you look further back in time, you can see that network show longevity has hints of being a zero-sum game. When one network has long-lived shows during a time period, such as ABC in the mid-1980s, another network might have a series of duds, such as NBC during the same time. This is reasonable, as there is only a finite amount of collective attention that we can lavish on television watching. Therefore if one network is doing well, it is not surprising that others do more poorly. Of course, this metric is far from perfect, but it can be used to test further hypotheses.

You can also notice other things in this chart, such as even historical events. For example Rossman has pointed out to me that there are hints of the 1988 writers strike, displayed as a precipitous drop in show length, though the 2007 strike is invisible.

As Ive already noted, we are in the middle of a great time for television. Maybe its also a great time for the applied mathematics of television as well.

Top image: urbanora/Flickr/CC-licensed

Visit link:
Television Show Longevity by Network

Online dating scammers looking for money, not love

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- Online romance scams, a new form of cybercrime, is under-reported and increasing, and has victimized an estimated 230,000 people in England, costing them nearly $60 billion a year, according to an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online at the Cyberpsychology, Behavior, and Social Networking website at http://www.liebertpub.com/cyber.

"This crime is very serious and unfortunately often overlooked. The costs to the victim are both hidden (emotional) and more visible (monetary)," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior and Social Networking, from the Interactive Media Institute, San Diego, CA.

Online dating scammers pretend to initiate a romantic relationship through online dating services and then defraud their victims of large sums of money over a period of months or longer. Monica Whitty, University of Leicester, UK, and Tom Buchanan, University of Westminster, London, UK, document the rapid growth in these serious crimes and how cybercriminals pursue and steal from their victims. They describe the devastating financial and emotional losses the victims suffer.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is an authoritative peer-reviewed journal published monthly in print and online that explores the psychological and social issues surrounding the Internet and interactive technologies. Complete tables of content and a sample issue may be viewed online at the Cyberpsychology, Behavior, and Social Networking website at http://www.liebertpub.com/cyber.

About the Company

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. website at http://www.liebertpub.com.

Original post:
Online dating scammers looking for money, not love

Innovative cell printing technologies hold promise for tissue engineering R&D

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- A novel method for printing human cells onto surfaces in defined patterns can help advance research on tissue engineering and regeneration, as described in an article in Tissue Engineering, Part C, Methods, a peer-reviewed journal from Mary Ann Liebert, Inc (http://www.liebertpub.com). The article is available free online at the Tissue Engineering website (http://www.liebertpub.com/ten).

"Cell printing is one of the breakthrough technologies that will make the application of stem cells for tissue engineering feasible," says John Jansen, DDS, PhD, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands.

Yu Fang and colleagues, University of Michigan, Ann Arbor, combined two microscale techniques to dispense and position cells in a variety of patterns. They then demonstrated the ability to use these 3-dimensional cell systems to monitor cell signaling events known to have a role in the growth, proliferation, and metastasis of cancer cells. The authors describe the use of sound waves to deliver microdroplets of cells and polymer-based phase separation to control cell placement in the article "Rapid Generation of Multiplexed Cell Co-Cultures Using Acoustic Droplet Ejection Followed by Aqueous Two-phase Exclusion Patterning." (http://online.liebertpub.com/doi/abs/10.1089/ten.TEC.2011.0709)

###

About the Journal

Tissue Engineering (http://www.liebertpub.com/ten) is an authoritative peer-reviewed journal published monthly in print and online in three parts: Part A--the flagship journal; Part BReviews; and Part CMethods. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed online at the Tissue Engineering website (http://www.liebertpub.com/ten).

About the Company

Mary Ann Liebert, Inc.(http://www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy and HGT Methods, and Biopreservation and Biobanking. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at Mary Ann Liebert Inc. (http://www.liebertpub.com).

Here is the original post:
Innovative cell printing technologies hold promise for tissue engineering R&D

Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant

SAN DIEGO, March 28, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) today announced that researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin(R)-formulated DNA vaccine candidate with the potential to prevent transmission of malaria. Results of the initial testing, recently published in the journal Vaccine1, demonstrated that the malaria parasite life cycle was interrupted in mosquitoes fed with malaria-infected human red blood cells incubated with serum from vaccinated mice. Vical provided the DNA vaccine plasmid backbone and the adjuvant used in the research.

The malaria parasite advances through several life cycle stages in humans and through additional life cycle stages in mosquitoes. The transmission-blocking DNA vaccine candidate, formulated with Vical's Vaxfectin(R) adjuvant, expresses the Plasmodium vivax malaria parasite protein Pvs230, which is present in both human and mosquito stages of the parasite's life cycle. Anti-Pvs230 antibodies generated by vaccinated mice recognized the Pvs230 protein and interrupted the parasite's development in mosquitoes. The amino acid sequence of Pvs230 protein is also highly conserved among multiple field isolates of P. vivax, increasing the potential for a single vaccine to provide broad protection.

The mouse-generated Pvs230 antibodies, incubated with P. vivax-infected human red blood cells and then fed to mosquitoes, statistically reduced the number of parasites and the infection rate in mosquitoes. A Vaxfectin(R)-formulated malaria vaccine therefore has the potential to interfere with the transmission of P. vivax to humans through mosquitoes. This novel transmission-blocking approach may thereby protect the broader population from widespread malaria outbreaks. Further study of the vaccine candidate has been proposed by the authors.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Risks and uncertainties include whether any further development of a Vaxfectin(R)-formulated DNA vaccine for malaria will continue; whether malaria vaccine or other results in animal studies can be duplicated in human clinical trials; whether the malaria vaccine will be effective in blocking transmission of malaria through mosquitoes to humans; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

1Tachibana, M, et al. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine 30 (2012) 1807-1812; doi:10.1016/j.vaccine.2012.01.003 .

More:
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant

Posted in DNA

No DNA linking man to Lin murders

Murdered ... newsagent Min Lin and wife Lilly Lin. Source: The Daily Telegraph

NO DNA evidence has been found linking the man accused of the bashing murders of the Lin family to the crime, a court heard this morning.

The Supreme Court was told recent test results on items taken from the family's North Epping home had failed to provide any DNA connection to Robert Xie, 48, who was last year charged with the murders.

Xie has been accused of killing his brother-in-law, Epping newsagent Min Lin, his wife Yun Li "Lilly" Lin, two other family members and Lilly's sister Yun Bin "Irene" Lin.

The five family members were beaten to death inside their home on July 18, 2009.

Xie's barrister Graham Turnbull SC told a bail hearing this morning that none of his client's DNA had been found on any evidence found at the main crime scene.

"The deceased persons' DNA profile (also) hasn't been identified on any of the items belonging to (Xie) or as coming from his home address," he said.

Documents previously tendered in court revealed police found a bloody trail of footprints leading away from the crime scene.

Xie owned several pairs of ASICS runners that matched the footprints and he was later secretly filmed destroying boxes for the shoe, the prosecution said.

Police allege Xie acted alone in carrying out the killing.

Continue reading here:
No DNA linking man to Lin murders

Posted in DNA

DNA Traces Cattle Back To Ancient Times

March 28, 2012

A new genetic study confirms that modern domesticated cattle are descended from 80 domesticated wild oxen in the Near East over 10,500 years ago.

Scientists from CNRS, the National Museum of Natural History in France, the University of Mainz in Germany, and University College London (UCL) in the UK performed the study by extracting DNA from the bones of extracted domestic cattle found in Iran. These sites are believed to date back to the invention of farming and the area where cattle first became domesticated.

The international team of scientists found only small differences in the DNA from the Iranian excavation and modern day domestic cattle. What little difference there is, say the scientists, could come from different population histories. By analyzing the DNA with computer simulations, they believe the differences in DNA could only have arisen if a small number of animals were domesticated from the wild ox. They believe as few as 80 wild oxen are responsible for what we know now as modern, domestic cattle.

Results of this study are published in the current issue of the journal Molecular Biology and Evolution.

In a press release announcing the results, Dr Ruth Bollongino of CNRS, France, and the University of Mainz, Germany; lead author of the study, said, Getting reliable DNA sequences from remains found in cold environments is routine. That is why mammoths were one of the first extinct species to have their DNA read. But getting reliable DNA from bones found in hot regions is much more difficult because temperature is so critical for DNA survival. This meant we had to be extremely careful that we did not end up reading contaminating DNA sequences from living, or only recently dead cattle.

According to the scientists, it is important to the archeological study of domestication to note the number of original animals.

Prof Mark Thomas, geneticist and an author of the study based at the UCL Research Department of Genetics, Evolution and Environment: This is a surprisingly small number of cattle. We know from archaeological remains that the wild ancestors of modern-day cattle, known as aurochs, were common throughout Asia and Europe, so there would have been plenty of opportunities to capture and domesticate them.

Based at the University of Mainz, Germany, Professor Joachim Burger had this to say about the wild ox, Wild aurochs are very different beasts from modern domestic cattle. They were much bigger than modern cattle, and wouldnt have had the domestic traits we see today, such as docility. So capturing these animals in the first place would not have been easy, and even if some people did manage snare them alive, their continued management and breeding would still have presented considerable challenges until they had been bred for smaller size and more docile behavior.

Other archeological studies have shown other animals, not just cattle, were domesticated. Goats, sheep, and pigs have also been found to be domesticated in the Near East around the beginning of the farming age. It is much harder, however, to determine how many of these animals were domesticated. While traditional archeological techniques do not provide an entire picture as to how many animals were domesticated, genetic research helps to fill in these gaps.

Excerpt from:
DNA Traces Cattle Back To Ancient Times

Posted in DNA

DNA confirms body found is Grand Junction mom missing since 2007

DNA has confirmed that human remains found near a dry stream in Delta County earlier this month belong to Paige Birgfeld, a Grand Junction woman who went missing in June 2007.

Sgt. Matt Lewis said the DNA match last week was a formality because dental records all but confirmed the remains were those of 34-year-old Birgfeld, a mother of three young children who worked as an escort. Her charred car was found in a Grand Junction parking lot a few days after her disappearance.

Lewis said investigators are awaiting the results of tests by an forensic anthropologist this week or early next. The detailed study of the remains "could help our coroner determine a cause and manner of death, which at this point would be huge."

He said those results might not be made public, however, if releasing them would benefit whoever might be responsible for Birgfeld's death or otherwise jeopardize the investigation.

Frank Birgfeld of Centennial said the area around the dry creek bed where his daughter's remains were found March 7 had been searched thoroughly in 2007. Her checkbook and other items from her purse were found along U.S. 50 not far away after her disappearance.

Read more here:
DNA confirms body found is Grand Junction mom missing since 2007

Posted in DNA

Applied DNA Sciences and Holliston to Incorporate Botanical SigNature DNA as the Next Generation Security Platform for …

STONY BROOK, NY--(Marketwire -03/28/12)- Applied DNA Sciences, Inc. (OTC.BB: APDN.OB - News), a provider of DNA-based security, anti-counterfeiting technology, law-enforcement and product-authentication solutions, and Holliston LLC, announced today they are working together to develop the next generation security platform for various product coatings, including passports and luxury packaging materials, with botanical SigNature DNA. As the nation's oldest and largest manufacturer of cloth coverings, Holliston has served the book cover material, packaging fabric, and industrial cloth markets since 1895. Holliston remains the U.S. Government's preferred supplier of high-security passport cover material.

Holliston's Chief Operating Officer, Keith Polak, stated: "We are excited about the prospect of incorporating the botanical SigNature DNA layer into a variety of products to stem the rising threat of forged passports and other identity documents. DNA, we believe, is the gold standard, and we are working toward providing our customers with the best security solution, whilst maintaining the highest quality products to which they are accustomed."

Applied DNA Sciences and Holliston are developing and testing DNA-coatings that essentially cannot be copied, and provide a means for customs and law enforcement groups to authenticate products in the field, and in the lab. The joint work has resulted in a feasibility study that successfully demonstrated the ability to incorporate botanical SigNature DNA onto passport covers. The next phase of the collaboration is to develop working prototypes, and move toward scaling up the process for commercial production.

Dr. James Hayward, APDN CEO and President, stated: "Passport authenticity governs secure entry into the United States for all citizens and visitors. We are pleased to be working with Holliston, the world's largest supplier of secure passport bindings. This effort extends our existing business to enhance government security."

About APDNAPDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

About HollistonICG Holliston is the nation's oldest and largest manufacturer of cloth coatings. At Holliston, we combine innovation, sustainability, and more than a century of experience to produce the highest quality, best-performing cotton cloth in the industry. From book covers to packaging, passports and industrial coverings, Holliston cloth is both distinctive and environmentally friendly -- and, it's made to stand up to the test of time.

Read more:
Applied DNA Sciences and Holliston to Incorporate Botanical SigNature DNA as the Next Generation Security Platform for ...

Posted in DNA

Critics raise safety concerns with biotech labs at Berkeley forum

No one disputes that the Lawrence Berkeley National Laboratory campus that's coming to Richmond will generate jobs and tax revenues.

But concerns persist about the work that will be done there, especially in synthetic biology, and the risks posed to the surrounding community.

That was among the topics at a news conference and public forum in Berkeley on Wednesday, touted as the first gathering in the area of local, national and international speakers to address concerns about synthetic biology, an emerging science that implants genetic material into cells to produce fuels and other industrial products.

Titled "Bay Area Biotech Labs Bring Unforeseen Risks," the panel presentation at the Center for Genetics and Society featured five prominent critics of synthetic biology.

The national lab, which selected Richmond for its next site thanks in part to broad support among Richmond city leaders, is not all that it appears, said panelist Gopal Dayaneni, co-director of the Movement Generation Justice and Ecology Project.

"What we're experiencing (with LBNL) is a wolf in sheep's clothing," Dayaneni said. "Actually, a wolf genetically engineered to look like a sheep."

Dayaneni, like the other panelists, said the lab enjoys the "shiny veneer" of legitimacy lent by UC Berkeley but is actually a secretive, poorly regulated merger of public and private interests that will be operating on the scientific fringes with potentially

"(Synthetic biology) is genetic engineering on steroids," said Jim Thomas of the ETC Group, a watchdog organization that monitors emerging technologies. "It's a $1.6 billion industry, and the Bay Area is absolutely the heart of that. ... A key institution is the new Richmond lab."

Panelists called for safeguards to bar "human applications" of synthetic biology, a more robust regulatory structure and better protections for workers.

Becky McLain, a molecular biologist who won a 2010 lawsuit against her former employer, pharmaceutical giant Pfizer, said the safety risks that may face workers in Richmond will be even more volatile than those she encountered in an embryonic stem cell lab. A federal jury awarded McLain $1.37 million in damages after she was exposed to a genetically engineered virus that caused her recurring paralysis and other illnesses.

Go here to see the original:
Critics raise safety concerns with biotech labs at Berkeley forum

Biology students contribute to science community, preterm birth research

Three biology students held a symposium to present their research on causes of preterm birth, the mechanism itself and treatment options earlier this month.

Bao-Tran Nguyen, John Schwabe and Siobhan Donnelly presented their theses and will graduate and pass on their part of the research this May.

"We're going to have students working on this for years," Schwabe said. "It's great to be a part of research with this magnitude and breadth, especially as an undergraduate."

A total of ten students are currently working on the project with Chishimba Mowa, an associate professor in the department of biology.

Nguyen said Mowa's lab is one of the few looking specifically at cervical remodeling to understand why preterm births occur.

"Sometimes it's frustrating because there's not a lot of previous studies, so we have to forage our own way and invent the wheel," Nguyen said.

This type of research is important because preterm birth is the leading cause of newborn death, Nguyen said.

Nguyen, Schwabe and Donnelly plan to publish their findings, Schwabe said.

"We're going to be the first people to publish this kind of study on this tissue," Schwabe said. "We've identified proteins previously unstudied in the cervix that may play a pivotal role in controlling natural birth."

Other students working on this research project are looking into herbs like Echinacea as a treatment option for preterm birth, Donnelly said.

Go here to read the rest:
Biology students contribute to science community, preterm birth research

Guyabano – Cancer Cure Discovered?

"Cancer Cure Discovered : Guyabano - The Soursop Fruit!" This article was forwarded to us by email by no less than former House of Representatives member and incumbent DavOr vice governor Mayo Almario. We also found out that

posted this on Facebook.

Why are we not aware of this? Because some big corporations want to make back their money spent on years of research by trying to make a synthetic version of it for sale.

So, since you know it now you can help a friend in need by letting him/her know or just drink some sour sop juice yourself as prevention from time to time. The taste is not bad after all. Its completely natural and definitely has no side effects. If you have the space, plant one in your garden. The other parts of the tree are also useful. The next time you have a fruit juice, ask for a SOUR SOP.

How many people died in vain while this billion-dollar drug maker concealed the secret of the miraculous Graviola tree?

This tree is low and is called graviola in Brazil, guanabana in Spanish and has the uninspiring name "sour sop" in English. The fruit is very large and the subacid sweet white pulp is eaten out of hand or, more commonly, used to make fruit drinks, sherbets and such.

The principal interest in this plant is because of its strong anti cancer effects. Although it is effective for a number of medical conditions, it is its anti tumor effect that is of most interest.

This plant is a proven cancer remedy for cancers of all types!

Besides being a cancer remedy, graviola is a broad spectrum antimicrobial agent for both bacterial and fungal infections, is effective against internal parasites and worms, lowers high blood pressure and is used for depression, stress and nervous disorders.

If there ever was a single example that makes it dramatically clear why the existence of Health Sciences Institute is so vital to all concerned and especially Americans like you, it's the incredible story behind the Graviola tree.

The rest is here:
Guyabano - Cancer Cure Discovered?

Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis

By Molika Ashford

Genoptix, the medical laboratory within Novartis's molecular diagnostics unit, has launched a targeted sequencing-based test for mutations in BRAF, NRAS, and c-KIT to help physicians tailor treatment for metastatic melanoma patients.

The NexCourse Melanoma sequencing profile, offered through Genoptix's CLIA lab, is the company's first sequencing-based test service and is already being ordered by physicians, according to the firm. Genoptix's President Tina Nova declined to provide details on how the test is being used so far but did tell PGx Reporter in an e-mail that the panel is not being used to place patients into clinical trials for Novartis drugs.

The company sees the service as a tool to help inform treatment decisions for patients with metastatic melanoma by screening for clinically relevant mutations in three genes associated with different prognoses and potential responses to targeted treatments.

However, the NGS profile is "not intended as a test for any specific drugs;" is not linked to any drugs in Novartis' pipeline targeting BRAF, NRAS or c-KIT mutations; and the company is not using the NGS profile to place patients into clinical trials involving drugs in development, "nor do we have any plans to do so," Nova wrote.

And although the service will assess BRAF mutations including V600E and V600K mutations it is not intended to guide treatment with Roches Zelboraf, which is indicated for BRAF V600E mutation-positive metastatic melanoma. The US Food and Drug Administration approved the drug in August alongside Roche's internally developed companion test, the Cobas 4800 BRAF V600 Mutation Test.

"Our focus in Genoptix is on providing physicians with the most relevant clinical information. We believe that NGS technology is going to factor heavily in the diagnosis and treatment of patients in the future," Nova said.

Novartis acquired Genoptix in January 2011 and the business falls within Novartis Molecular Diagnostics, a unit formed around three years ago. The primary focus of the Novartis MDx business is companion diagnostics, but the company is also pursuing a "complementary diagnostics" strategy, which includes tests that don't require extensive coordination between drug and diagnostic development arms or simultaneous drug/test approval by the FDA (PGx Reporter 12/7/2011).

Nova did not detail Genoptixs hopes for the testing service beyond offering a more comprehensive test than currently available single-gene assays to help physicians tailor treatment for each patient.

"The NGS profile provides us with a much more comprehensive picture of the tumor than with assays that target specific point mutations, she said.

Continue reading here:
Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis

University of Miami’s nanotechnology institute gets $7.5 million donation

The University of Miamis biomedical nanotechnology institute got a little closer to finding a cure for blindness and diabetes and improving cancer treatment, thanks to a $7.5 million donation announced Tuesday.

The Dr. John T. Macdonald Foundation provided the donation. The institute will be renamed in honor of the foundation, which has donated $38 million to medical research and scholarships since 1992, said Kim Greene, the centers executive director.

We think that nanotechnology is on the leading edge of science and medicine, and can literally change peoples lives and upgrade the technology that we currently use for things such as blindness and chemotherapy, Greene said.

Biomedical nanotechnology research involves working with everyday materials such as carbon, but on a nano-scale which is less than one-millionth of a millimeter in size in order to treat and cure medical conditions.

Its extremely small. In fact its getting to the size of molecules, said Dr. Richard J. Cote, director of the institute.

The foundations donation will go in part toward building a clean room in which nano machines and nano devices can be built.

Were talking about something that is much, much cleaner than an operating room in which there is no dust whatsoever, said Cote. Because, you can imagine, when youre working on a very small scale, a piece of dust is like a boulder.

The donation also allows the institute to conduct new research for which there isnt much supporting research making it hard to get funding from more common sources such as the government, Cote said.

The facility, now named the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute, has been around for about three years. It brings together investigators from UMs Miller School of Medicine, College of Arts and Sciences and the College of Engineering, and several university departments.

The institute needs to have expertise from a variety of disciplines in order to be comprehensive, Cote said.

Link:
University of Miami’s nanotechnology institute gets $7.5 million donation

‘Mini medical school’

March 28, 2012 Mini medical school FSHS students visit West Virginia School of Osteopathic Medicine

By Mary Wade Burnside Times West Virginian The Times West Virginian Wed Mar 28, 2012, 05:01 AM EDT

FAIRMONT Austin Patterson wants to pursue a career as an orthopedic surgeon, and getting to perform such medical functions as an intubation putting a tube down an airway passage of a mannequin during a visit to the West Virginia School of Osteopathic Medicine encouraged his dream.

We got to try two different tools to do it and decide which one we liked better and which one was easier,Patterson said.

Instead of deterring him from his desire to be an orthopedic surgeon an idea he

got from his godfather, who practices at United Hospital Center It influenced me more,said the Fairmont Senior High School student.

Patterson was among 13 Fairmont Senior students who traveled to the school, located in Lewisburg, to talk to current medical students and learn more about the types of scenarios and conditions that they will get to in the future if they do decide to pursue medicine as a career.

Full story

More:
‘Mini medical school’

More U. doctors

More U. doctors

The shortage of seats in the University of Utah medical school means that some of the Beehive States brightest youths will leave for medical school elsewhere and the potential for Utah to add to its pool of primary-care doctors will shrink.

The state so far has not seen a critical shortage of primary-care doctors, even though doctors in Utah are paid only two-thirds the national average, but that could change quickly. Rural areas already have a hard time keeping physicians in town.

The Utah Legislature decided not to restore the U. medical school classes to 102, an increase of 20 over the current number, set in 2010 because of declining revenue. The U. medical school gets just 4 percent of its budget from state funds, while the national mean for public university medical schools is 14 percent.

U. administrators say the medical school, the only one for 500 miles, should have an enrollment of 122 per class and they have proposed a deal to share costs that would increase annual contributions from state coffers by $9.6 million and from the U.s clinical departments by $12 million.

That is a sensible way to prevent Utah finding itself with a critical shortage of "family doctors," who are the first line of defense in health care, as other states are facing. Besides the low medical-school enrollment, the states relatively low pay for physicians, especially those in primary care, could mean more undergraduates leaving Utah to study and then practice elsewhere.

The alternative of raising tuition would result in medical-school graduates going deeper in debt to finance their training and then potentially being lured into medical specialties, rather than family practice, in order to repay loans and support families.

The Legislature was generous in filling some requests from higher education officials in its session just ended. But the university is farsighted in continuing to press for additional medical school funding to boost enrollment.

Its important to those bright young Utahns who want to train and practice as doctors in their home state so they can raise their families here. The U. recognizes that and reserves 70 percent of slots for Utah residents.

And its important, not only to families with children but also the growing elder population. The number of Utahns65andolder is expected grow by 50 percent between 2000 and2015, and by 155 percent by 2030. Their need for medical services will grow just as fast. The state has a duty to meet those needs.

See the article here:
More U. doctors

Medical school denied funding to increase class size

by: Tyler North on March 28, 2012

Med school employees Scott Kimberlin and Sage Bates make their way to the Neurosurgery Department Tuesday at the School of Medicine.

The School of Medicine was recently denied funding for a class size increase by the Utah Legislature.

Currently, the School of Medicine accepts 82 students per year to its program, a drop of 20 students from 2010. Lack of funding and many other reasons caused the school to decrease its size during the past two years.

In the recent legislative session, higher education in Utah received an overall boost in the budget, but the School of Medicines initiative was turned down.

I was disappointed we didnt fund the medical school, but that is not to say we didnt give plenty to higher education, said Sen. Ross Romero, D-Salt Lake City, who supported the School of Medicines initiative. We helped higher education by increasing the budget by three percent.

Utah is ranked No. 46 nationally in the number of physicians per population with the projection for physician supply worsening in the future, according to the School of Medicines web page.

We really do have a shortage of physicians and especially in pediatrics and rural areas, said Chris Nelson, Health Sciences spokesman. For this reason, our top priority is to grow the class size over the next two years.

The School of Medicine received 1,500 applicants for its 82 positions in 2011. Under the proposed plan, the School of Medicine first intends to restore class sizes to 102 students and then increase accepted applicants to 122 as soon as possible.

Just to restore it back to 102 is $6 million per year, Nelson said.

See the rest here:
Medical school denied funding to increase class size

MU names new medical school dean

HUNTINGTON, W.Va. -- Marshall University has tapped a veteran kidney disease researcher from Ohio to take over as dean of its struggling medical school.

Dr. Joseph Shapiro, chairman of the department of medicine at the University of Toledo College of Medicine, will step in as Marshall's medical dean on July 1. The Marshall medical school faces big staffing and curriculum problems identified by its primary accrediting body.

"I'm truly excited and enthralled with the opportunity to lead this terrific medical school into the future," Shapiro told a large audience at Marshall's campus on Tuesday. "We face some challenges, some might say crisis, but out of crisis we're going to find opportunity to serve the population of West Virginia and make this part of the world a better place."

The School of Medicine was placed on probation in June by the Liaison Committee on Medical Education for a lack of diversity, lack of scholarly activity, a poorly integrated curriculum and a breakdown in student advising.

"Our real problem was infrastructure," said Dr. Robert Nerhood, interim dean of the School of Medicine. "We had too few faculty to do too much, and a consequence of that was that some things didn't get done."

The LCME identified 10 areas of concern in a June 15 letter to Marshall University President Stephen Kopp, among them a lack of debt counseling and career advising.

According to the letter, 32 percent of students who graduated in 2010 left the school with debt of more than $200,000.

The school has two years to correct the problems and must tell all new students about the accreditation problems. Marshall appealed the LCME accreditation decision in October, but their request was denied.

HUNTINGTON, W.Va. -- Marshall University has tapped a veteran kidney disease researcher from Ohio to take over as dean of its struggling medical school.

Dr. Joseph Shapiro, chairman of the department of medicine at the University of Toledo College of Medicine, will step in as Marshall's medical dean on July 1. The Marshall medical school faces big staffing and curriculum problems identified by its primary accrediting body.

The rest is here:
MU names new medical school dean

USC medical school student could work in Florence

Officials are pondering a plan that would bring third- and fourth-year medical students from the USC School of Medicine to study in Florence beginning in 2014.

Officials from Francis Marion University, McLeod Regional Medical Center and the Carolinas Hospital System are pondering a plan that would bring third- and fourth-year medical students from the University of South Carolina School of Medicine to study in Florence beginning in 2014.

A meeting last week with an outside consultant was designed to give the participants a financial framework for the plan. The institutions involved would need to hire additional teaching and supervisory staff. The students 25 to begin with, with as many as 60 at some later date would work and study at Florence-area hospitals their last two years of medical school at USC.

The idea of opening a med school practicum in Florence stems from the recent decision to create a branch of the USC Med School in Greenville. The USC School of Medicine-Greenville is scheduled to enroll its first class of students this fall. When those students begin their third year in the new program, they will displace the nearly 60 USC students who currently complete their third and fourth years of study in Greenville.

Because the new Greenville school represents an expansion of the USC School of Medicines enrollment, the school will need to find a new place for those students.

Local officials here say Florence is a natural choice. The Pee Dee area is about to become the only area of the state without a med school (the state will have medical schools in Columbia and Charleston, as well as the new school in Greenville), and Florence already has extensive medical facilities.

It would be a great fit, said Dr. Eddie Floyd, a local cardiologist and philanthropist who is shepherding the plan. Were all working together on this and it will really enhance what we have to offer, both as a city and a medical community.

MCT

See the original post here:
USC medical school student could work in Florence

Shapiro named Marshall medical school dean

HUNTINGTON, W.Va. -- Dr. Joseph I. Shapiro was named dean of Marshall University's medical school on Tuesday.

Shapiro currently serves as associate dean for business development and medical chairman at the University of Toledo's College of Medicine. He was picked through a nationwide search that started last summer.

"It is a great honor and privilege to be associated with this fabulous organization, and I firmly believe that the coming years will present great opportunity for the school to expand its purview in the areas of education, research and service as we pursue our mission to improve the health of West Virginia," Shapiro said.

Shapiro's appointment comes five months after an accrediting body placed the medical school on probation due to noncompliance with accreditation standards in several areas.

Marshall President Stephen J. Kopp highlighted Shapiro's work in academic medicine, research knowledge and clinical and business experience.

"More than anything else, however, we believe he embraces the ideals that distinguish our School of Medicine, and he knows the direction we must take to continue to build on the great tradition and proud heritage at Marshall," Kopp said.

Shapiro has more than 30 years of clinical and teaching experience and specializes in kidney care. He succeeds Dr. Robert C. Nerhood, who had been serving as interim dean of the Joan C. Edwards School of Medicine.

Dr. Charles McKown stepped down as dean last year to become the Huntington school's vice president for health sciences advancement.

Shapiro has served as an investigator on nearly three dozen grant-funded projects totaling more than $30 million. He has been involved with the creation of three spin-off companies from that research. In addition, he holds patents on 14 medical inventions and has written more than 100 research articles.

In October, the Liaison Committee on Medical Education denied Marshall's appeal of its June 2011 recommendation of probation for the Joan C. Edwards School of Medicine. Under the committee's rules of procedure, programs on probation retain their accreditation. But the committee can revoke the accreditation if any noncompliance is detected within a two-year period.

Read the rest here:
Shapiro named Marshall medical school dean

Why this could kill you

Next time you're on a bus or train, holding on to a pole to avoid a fall, cranky that another commuter has nabbed the last seat, consider the fact that standing up could boost your longevity.

Not only do we need to get more exercise but we also need to spend less of our time sitting down, Australian researchers say.

Advertisement: Story continues below

Their study of more than 220,000 NSW residents found the longer you spend sitting down the greater your risk of dying early, even if you otherwise do regular exercise.

Professor David Dunstan, from the Baker IDI Heart and Diabetes Institute, said health workers usually focused on trying to increase people's participation in sports, and trying to get them to do at least half an hour of exercise every day.

"We need to think more about what we do with the 15 hours of non-exercise wake time," he said.

Sitting can be detrimental for our health because when we sit down there is an absence of muscle contractions, explains Professor Dunstan. These contractions are required for the body to clear blood glucose and blood fats from the blood stream.

Studies on animals have shown that when the body stops moving for long periods of time it slows down one of the key enzymes needed to break down blood fats.

The study, published in the Archives of Internal Medicine, found adults who sat for more than 11 hours a day had a 40 per cent increased risk of dying within three years, compared with those who sat for fewer than four hours a day.

People who sat for eight to 11 hours a day increased their risk of dying by 15 per cent.

More:
Why this could kill you